Compare Merck & Co., Inc. (MRK) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance

Merck & Co., Inc.Trade

TAKE-TWO INTERACTIVE SOFTWARE, INC Common StockTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Merck & Co., Inc. trades at $126.19 (market cap $307.25B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $235.5 (market cap $44.37B). The key difference: Merck & Co., Inc. is far larger — about 6.9× TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock's market cap, and Merck & Co., Inc. pays a 2.73% dividend while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock pays none. Which is the better fit depends on your goals.

	MRK	TTWO
Market Cap	$307.25B	$44.37B
Sector	Health	Media
52-Week High	$129.52	$262.29
52-Week Low	$77.60	$189.69
Enterprise Value	$350.66B	$45.34B
Dividend Yield	2.73%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.

The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.

TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 4 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 1 day agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

TTWO

Take-Two's Q1 expected in line; focus on GTA VI release and updatesProactive Investors · 4 days agoNeutral View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock

Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.